Pfizer has indicated that they will not be making a submission to NICE for the above indication until the outcome of the palboclicib plus an aromatase inhibitor appraisal [ID915] is final. In the meantime appraisal [ID916] will be suspended while NICE considers the options for rescheduling.
 
Status Suspended
Process STA
ID number 916

Project Team

Project lead Liv Gualda

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 February 2017 Suspended, Pfizer has indicated that they will not be making a submission to NICE for the above indication until the outcome of the palboclicib plus an aromatase inhibitor appraisal [ID915] is final. In the meantime appraisal [ID916] will be suspended while NICE considers the options for rescheduling.
23 November 2016 The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has now been rescheduled. The first committee meeting will take place in June 2017.
20 October 2016 The technology appraisal of palbociclib in combination with fulvestrant for hormone-receptor positive, HER2-negative breast cancer after endocrine therapy [ID916] has been suspended at the request of Pfizer. The Company submission of a value proposition for palbociclib after endocrine therapy will follow after the outcome of the appraisal of palbociclib for previously untreated disease [ID915] is known.
06 October 2016 Invitation to participate
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance